225 related articles for article (PubMed ID: 26608463)
1. Osteoprotegerin secreted by inflammatory and invasive breast cancer cells induces aneuploidy, cell proliferation and angiogenesis.
Goswami S; Sharma-Walia N
BMC Cancer; 2015 Nov; 15():935. PubMed ID: 26608463
[TBL] [Abstract][Full Text] [Related]
2. Crosstalk between osteoprotegerin (OPG), fatty acid synthase (FASN) and, cycloxygenase-2 (COX-2) in breast cancer: implications in carcinogenesis.
Goswami S; Sharma-Walia N
Oncotarget; 2016 Sep; 7(37):58953-58974. PubMed ID: 27270654
[TBL] [Abstract][Full Text] [Related]
3. Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression.
Schubert A; Schulz H; Emons G; Gründker C
Gynecol Endocrinol; 2008 Jun; 24(6):331-8. PubMed ID: 18584413
[TBL] [Abstract][Full Text] [Related]
4. Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours.
Van Poznak C; Cross SS; Saggese M; Hudis C; Panageas KS; Norton L; Coleman RE; Holen I
J Clin Pathol; 2006 Jan; 59(1):56-63. PubMed ID: 16394281
[TBL] [Abstract][Full Text] [Related]
5. Osteoprotegerin mediates tumor-promoting effects of Interleukin-1beta in breast cancer cells.
Chung ST; Geerts D; Roseman K; Renaud A; Connelly L
Mol Cancer; 2017 Feb; 16(1):27. PubMed ID: 28143606
[TBL] [Abstract][Full Text] [Related]
6. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
[TBL] [Abstract][Full Text] [Related]
7. Potential role of the OPG/RANK/RANKL axis in prostate cancer invasion and bone metastasis.
Li X; Liu Y; Wu B; Dong Z; Wang Y; Lu J; Shi P; Bai W; Wang Z
Oncol Rep; 2014 Dec; 32(6):2605-11. PubMed ID: 25333856
[TBL] [Abstract][Full Text] [Related]
8. Tumor necrosis factor-α enhances RANKL expression in gingival epithelial cells via protein kinase A signaling.
Fujihara R; Usui M; Yamamoto G; Nishii K; Tsukamoto Y; Okamatsu Y; Sato T; Asou Y; Nakashima K; Yamamoto M
J Periodontal Res; 2014 Aug; 49(4):508-17. PubMed ID: 24102429
[TBL] [Abstract][Full Text] [Related]
9. Expression of receptor activator of nuclear factor kappa-B as a poor prognostic marker in breast cancer.
Park HS; Lee A; Chae BJ; Bae JS; Song BJ; Jung SS
J Surg Oncol; 2014 Dec; 110(7):807-12. PubMed ID: 25111682
[TBL] [Abstract][Full Text] [Related]
10. Effects of icariin on the regulation of the OPG-RANKL-RANK system are mediated through the MAPK pathways in IL-1β-stimulated human SW1353 chondrosarcoma cells.
Wang Z; Ding L; Zhang S; Jiang T; Yang Y; Li R
Int J Mol Med; 2014 Dec; 34(6):1720-6. PubMed ID: 25270538
[TBL] [Abstract][Full Text] [Related]
11. Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis.
Nyambo R; Cross N; Lippitt J; Holen I; Bryden G; Hamdy FC; Eaton CL
J Bone Miner Res; 2004 Oct; 19(10):1712-21. PubMed ID: 15355567
[TBL] [Abstract][Full Text] [Related]
12. 17beta-Estradiol inhibits osteoprotegerin production by the estrogen receptor-alpha-positive human breast cancer cell line MCF-7.
Rachner TD; Schoppet M; Niebergall U; Hofbauer LC
Biochem Biophys Res Commun; 2008 Apr; 368(3):736-41. PubMed ID: 18252198
[TBL] [Abstract][Full Text] [Related]
13. Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection.
Park HS; Park WS; Bondaruk J; Tanaka N; Katayama H; Lee S; Spiess PE; Steinberg JR; Wang Z; Katz RL; Dinney C; Elias KJ; Lotan Y; Naeem RC; Baggerly K; Sen S; Grossman HB; Czerniak B
J Natl Cancer Inst; 2008 Oct; 100(19):1401-11. PubMed ID: 18812553
[TBL] [Abstract][Full Text] [Related]
14. Salubrinal Exposes Anticancer Properties in Inflammatory Breast Cancer Cells by Manipulating the Endoplasmic Reticulum Stress Pathway.
Alsterda A; Asha K; Powrozek O; Repak M; Goswami S; Dunn AM; Memmel HC; Sharma-Walia N
Front Oncol; 2021; 11():654940. PubMed ID: 34094947
[TBL] [Abstract][Full Text] [Related]
15. DNA methylation and histone modification regulate silencing of OPG during tumor progression.
Lu TY; Kao CF; Lin CT; Huang DY; Chiu CY; Huang YS; Wu HC
J Cell Biochem; 2009 Sep; 108(1):315-25. PubMed ID: 19565568
[TBL] [Abstract][Full Text] [Related]
16. Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers.
Widschwendter M; Burnell M; Fraser L; Rosenthal AN; Philpott S; Reisel D; Dubeau L; Cline M; Pan Y; Yi PC; Gareth Evans D; Jacobs IJ; Menon U; Wood CE; Dougall WC
EBioMedicine; 2015 Oct; 2(10):1331-9. PubMed ID: 26629528
[TBL] [Abstract][Full Text] [Related]
17. Importance of osteoprotegrin and receptor activator of nuclear factor κB in breast cancer response to hepatocyte growth factor and the bone microenvironment in vitro.
Owen S; Sanders AJ; Mason MD; Jiang WG
Int J Oncol; 2016 Mar; 48(3):919-28. PubMed ID: 26781475
[TBL] [Abstract][Full Text] [Related]
18. Effects of Enterococcus faecalis lipoteichoic acid on receptor activator of nuclear factor-κB ligand and osteoprotegerin expression in periodontal ligament fibroblasts.
Zhao L; Chen J; Cheng L; Wang X; Du J; Wang F; Peng Z
Int Endod J; 2014 Feb; 47(2):163-72. PubMed ID: 23710898
[TBL] [Abstract][Full Text] [Related]
19. [Inhibitory acting mechanism of psoralen-osthole on bone metastasis of breast cancer--an expatiation viewing from OPG/RANKL/RANK system].
Sheng L; Wu CY; Chen XF
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2011 May; 31(5):684-9. PubMed ID: 21812275
[TBL] [Abstract][Full Text] [Related]
20. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway.
Luo XH; Guo LJ; Xie H; Yuan LQ; Wu XP; Zhou HD; Liao EY
J Bone Miner Res; 2006 Oct; 21(10):1648-56. PubMed ID: 16995820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
